Association Between Thyroid Dysfunction & Intensive Care Unit Acquired

Status Recruiting

Clinical Trial Summary

Intensive care unit-acquired weakness (ICU-AW) is the most common neuromuscular impairment in critically ill patients. It affects more than 50 % of patients in the intensive care and is related to many problems as difficult weaning from mechanical ventilation, prolonged hospital stay and increased mortality.Thyroid disorders are also associated with neuromuscular abnormalities and may decrease the threshold for the development of any type of myopathy. However, no previous study investigated the direct relationship between thyroid dysfunction and ICUAW.This study aims at evaluation of the association between thyroid dysfunction and intensive care unit acquired weakness.

Clinical Trial Description

Intensive care unit acquired weakness refers to muscle weakness encountered in the intensive care unit as a consequence of critical illness. It affects more than 50 % of patients in the intensive care and is related to many problems as difficult weaning from mechanical ventilation, prolonged hospital stay and increased mortality.

There are three distinct entities for ICUAW that can only be differentiated by neurophysiological studies. These are critical illness myopathy (CIM), critical illness polyneuropathy (CIP) and critical illness neuromyopathy (CINM).

Identification of risk factors responsible for the development of ICUAW is the first step in the prevention and management of this disorder. Till time septic shock, hyperglycemia, high dose steroid therapy, prolonged mechanical ventilation and the use of neuromuscular blocking agents are the main accused.

Thyroid disorders are also associated with neuromuscular abnormalities. Unfortunately, the prevalence of thyroid dysfunction in the intensive care is high reaching 90%. Moreover, patients with severe critical illness, who are typically prone to the development of ICUAW, show changes in their thyroid biochemistry namely low T3 levels (with or without low T4 levels) in the presence of normal TSH levels. These changes are collectively known as Non-Thyroidal illness syndrome (previously low T3 syndrome and Euthyroid sick syndrome) which is the most common form of thyroid dysfunction in the intensive care unit. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04313101
Study type	Observational
Source	Ain Shams University
Contact	Tarek S Shabana, MD
Phone	01001594109
Email	tarek.shabana@hotmail.com
Status	Recruiting
Phase
Start date	February 20, 2020
Completion date	May 2020

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04430283` - Evaluation of FDY-5301 in Major Trauma Patients in ICU	Phase 2
Completed	`NCT05527678` - 5 Years Quality of Life and Early Mobilization in ICU
Recruiting	`NCT05537298` - Muscle Recovery After Critical Illness
Completed	`NCT05473546` - Diarrhea and Stipsis in Critically Ill Patients (NUTRITI)
Not yet recruiting	`NCT05326633` - Effect of Protein, Mobility Therapy and Electric Stimulation on Recovery in Older ICU Survivors	Early Phase 1
Not yet recruiting	`NCT06025760` - Evaluation of Diaphragmatic Function and Quadriceps Muscle Thickness in Patients Receiving High Protein Nutrition	N/A
Completed	`NCT05048953` - The Use of Musculoskeletal Ultrasound for the Detection of ICU-Acquired Weakness
Terminated	`NCT04095533` - ICU Associated Weakness and Bedside Ultrasound Assessment
Terminated	`NCT04160039` - Early Cycle Ergometry for Critically-Ill Liver Failure Patients in a Transplant Intensive Care Unit	N/A
Active, not recruiting	`NCT04944537` - Current Situation and Analysis of ICU Management for Severe Trauma Patients in China
Recruiting	`NCT05865314` - Optimised Nutritional Therapy and Early Physiotherapy in Long Term ICU Patients (NutriPhyT Trial)	N/A
Completed	`NCT04810273` - Effect of Progressive Early Mobilization in Patients With TBI	N/A
Completed	`NCT04396197` - Physical Activity Levels in COVID-19 Patients Admitted to Intensive Care
Recruiting	`NCT04932330` - Risk Factors of ICU-acquired Weakness
Completed	`NCT05008562` - How COVID-19 Effects to Muscle Mass Change ın ICU?
Recruiting	`NCT05919940` - Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO )	N/A
Recruiting	`NCT04565002` - Transcutaneous Electrical Diaphragmatic Stimulation in Critically Ill Elderly Patients	N/A
Recruiting	`NCT05396066` - Respiratory and Quadriceps Muscle Fatigability After an ICU Acquired Weakness
Recruiting	`NCT04998643` - Muscle Catabolism and Outcomes in Children Following Cardiac Surgery
Not yet recruiting	`NCT06184945` - Behavioral Economic & Staffing Strategies in the ICU	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Association Between Thyroid Dysfunction and Intensive Care Unit Acquired Weaknesss

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms